Bio/pharma IPRs by the numbers
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Bio/pharma IPRs by the numbers

Figures discussed at the BIO International Convention reveal that bio/pharma IPRs at the Patent Trial and Appeal Board have a lower institution rate and lower claim-cancellation rate than for all IPRs

According to the USPTO’s latest statistics, there have been 108 PTAB petitions filed in the TC 1600 class covering bio/pharma patents. This is 8.1% of all petitions filed.

At the BIO International Convention, the USPTO’s Jackie Wright Bonilla provided further detail on how the TC 1600 class stacks up to others.

She revealed the TC 1600 class has a 64% institution rate for inter partes review (IPR) petitions. This is lower than the 76% institution rate for all IPRs.

The rate of claims being cancelled by the Board in pharma IPRs is also below the average. The TC 1600 class has had 28 final written decisions. In these, 75.5% of instituted claims were cancelled (309 claims cancelled and 100 claims found patentable) and 71.7% of challenged claims were cancelled.

In comparison, in the 323 final written decisions in all IPRs 82.5% of instituted claims have been cancelled and 75.3% of challenged claims have been cancelled.

In the same session, Sterne Kessler’s Eric Steffe gave an overview of PTAB cases that have been appealed to the Federal Circuit. He said 141 appeals from final IPR/CBM decisions were docketed at the Federal Circuit. Of these, 104 (75%) are by patent owners, 18 (13%) are by petitioners and 19 (12%) are cross appeals by both parties,

Nine percent of the appeals are from the biotech/chemistry area, with 13 appeals. Nine of these are by patent owners and four are by petitioners, which Steffe said is “roughly mirroring other technologies in terms of who is making those appeals”.



more from across site and ros bottom lb

More from across our site

An intimate understanding of a client’s sector is essential to winning new business, a survey of over 28,000 corporate counsel reveals
Counsel say a Federal Circuit ruling on the obviousness test for design patents may increase the time IP owners spend defending their rights
While the INTA Annual Meeting is over for another year, here are a few things Managing IP learned after attending IP’s biggest party
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Four sources reveal which tools they have been using – or building – to help them with a range of tasks from invention generation to claim sufficiency
Managing IP reveals Wednesday's highlights, including a discussion on how AI is helping lawyers improve their "gut instinct" trademark decisions
Managing IP reveals Tuesday’s highlights, including an illuminating discussion celebrating women in the workplace and the challenges that remain
Dana Northcott, INTA’s 2024 president and associate general counsel for Amazon's IP team, talks about her work for the association
Managing IP reveals highlights from the INTA Annual Meeting, including law firms’ diversity and ESG concerns and a new beginning for a Chinese firm
Firms with a broad geographic reach are more likely to win work, especially from global companies with high turnovers, according to survey data of nearly 29,000 corporate counsel
Gift this article